Evaluation of Bacterial RNA Polymerase Inhibitors in a -Based Wound Infection Model in SKH1 Mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Elgaher, Walid A M
Laschke, Matthias W
Hirsch, Anna K H
Murakami, Katsuhiko S
Hartmann, Rolf W
MetadataShow full item record
AbstractChronic wounds infected with pathogens such as Staphylococcus aureus represent a worldwide health concern, especially in patients with a compromised immune system. As antimicrobial resistance has become an immense global problem, novel antibiotics are urgently needed. One strategy to overcome this threatening situation is the search for drugs targeting novel binding sites on essential and validated enzymes such as the bacterial RNA polymerase (RNAP). In this work, we describe the establishment of an in vivo wound infection model based on the pathogen S. aureus and hairless Crl:SKH1-Hrhr (SKH1) mice. The model proved to be a valuable preclinical tool to study selected RNAP inhibitors after topical application. While rifampicin showed a reduction in the loss of body weight induced by the bacteria, an acceleration of wound healing kinetics, and a reduced number of colony forming units in the wound, the ureidothiophene-2-carboxylic acid 1 was inactive under in vivo conditions, probably due to strong plasma protein binding. The cocrystal structure of compound 1 with RNAP, that we hereby also present, will be of great value for applying appropriate structural modifications to further optimize the compound, especially in terms of plasma protein binding.
CitationACS Infect Dis. 2020 Oct 9;6(10):2573-2581. doi: 10.1021/acsinfecdis.0c00034. Epub 2020 Sep.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
PublisherAmerican Chemical Society (ACS)
JournalACS infectious diseases
The following license files are associated with this item:
- Creative Commons
- Development of Chitosan-Based Hydrogel Containing Antibiofilm Agents for the Treatment of Staphylococcus aureus-Infected Burn Wound in Mice.
- Authors: Chhibber T, Gondil VS, Sinha VR
- Issue date: 2020 Jan 2
- Binding mode characterization of novel RNA polymerase inhibitors using a combined biochemical and NMR approach.
- Authors: Fruth M, Plaza A, Hinsberger S, Sahner JH, Haupenthal J, Bischoff M, Jansen R, Müller R, Hartmann RW
- Issue date: 2014 Nov 21
- The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound.
- Authors: Hurtuk MG, He LK, Szilagyi A, Gamelli RL, Hecht DW, Kennedy RH, Rhys-Williams W, Love WG, Shankar R
- Issue date: 2010 May-Jun
- In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
- Authors: Desbois AP, Gemmell CG, Coote PJ
- Issue date: 2010 Jun
- Topical simvastatin promotes healing of Staphylococcus aureus-contaminated cutaneous wounds.
- Authors: Wang CC, Yang PW, Yang SF, Hsieh KP, Tseng SP, Lin YC
- Issue date: 2016 Dec